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Cytokine Concentration
IL-2 4000-8000pg/mL
IFNg 1000-3800pg/mL
IL-1b 300-1400pg/mL
TNFa 1000-4300pg/mL
Also contains measurable amounts 
of: IL-6, IL-8, GM-CSF, G-CSF
Conclusions and Future Directions
Primary Endpoint: Feasibility
Patient ID Age
Estrogen 
Receptor %
Progesterone 
Receptor %
HER2 status Grade Ki67% Tumor size
Lymph Node 
involvement
Pre-treatment 
sTIL score
Post-treatment 
sTIL score
IRXB-001 78 100% 100% Negative 2 11% 1.9cm Yes 8.75 12.5
IRXB-002 58 96.30% 90.10% Negative 2 19% 2.4cm Yes 13.75 13.75
IRXB-003 40 98% 100% Negative 2 17% 3.0cm Yes 1.75 1.75
IRXB-004 64 0% 0% Positive 3 75% 4.2cm Yes 6.25 13.75
IRXB-005 48 98% 92% Negative 1 7% 1.7cm Yes 3.75 3.75
IRXB-006 62 0% 0% Positive 3 73% 2.7cm Yes 18.75 13.75
IRXB-007 45 98 100 Negative 3 55% 3.7cm Yes 18.75 16.25
IRXB-008 54 100% 42% Negative 3 50% 2.1cm No 7.5 16.25
IRXB-009 56 100% 100% Negative 2 11% 0.7cm No 1 3
IRXB-010 46 100% 99% Negative 2 33% 1.8cm No 11.5 18.75
IRXB-011 52 69% 0% Positive 3 38% 1.5cm Yes 6.25 4
IRXB-012 52 98% 100% Positive 3 12% 2.1cm No 61.25 67.5
IRXB-013 59 100% 7% Negative 3 87% 2.2cm No 31.25 38.75
IRXB-014 45 100% 100% Negative 1 N/A 2.2cm No 1 1
IRXB-015 61 100% 50% Negative 2 30% 1.9cm No 3.5 6.75
IRXB-016 66 0% 0% Negative 3 95% 1.0cm No 1 13.75
Figure 1: Regimen
Methods
Hypothesis 
§ IRX-2 is an injectable cytokine-based immunotherapy containing
multiple cytokines derived from ex vivo phytohemagglutinin-
stimulated donor lymphocytes;
§ Measurable constituents include: IFN!, IL-2, IL-1b, TNF⍺, IL-6, IL-8,
GM-CSF, and G-CSF
§ In preclinical models, IRX-2 activates T cells and natural killer cells,
and facilitates dendritic cell maturation;
§ In a phase I trial, neoadjuvant IRX-2 increased tumor-infiltrating
lymphocytes (TILs) and shrank tumors in resectable head/neck
squamous carcinoma (HNSCC);1
§ Stromal TILs (sTILs) are associated with improved survival in early
stage breast cancer (ESBC).
§ Patients with early stage (I-III) breast cancer were enrolled pre-
operatively
§ Patients received low dose of cyclophosphamide (d1, 300 mg/m2) to
facilitate T-regulatory (T-reg) cell depletion2, followed by 10 days of
subcutaneous peri-areolar subcutaneous IRX-2 into the affected breast
(1 mL × 2 at tumor axis and at 90°), similar to sentinel lymph node
mapping methodology;
§ Subjects also received oral indomethacin, which may reverse
immunosuppression by modulating myeloid cells3
§ Primary endpoint: feasibility
§ Secondary endpoint: blinded assessment of sTILs by the 2015 San
Antonio working group criteria4
§ Exploratory endpoints: comprehensive immune monitoring
1. Whiteside T, et al., Cancer Immunol Immunother. 2012; 61:783-788.
2. Machiels J et al., Cancer Res. 2001;61:3689-3697.
3. Thun M et al., J Natl Cancer Inst. 2002;94:252-66.
4. Salgado R et al., Ann Oncol. 2015;26:259-271.
To assess the feasibility of preoperative IRX-2, and its effect on TIL
recruitment and immune priming within breast and HNN tumors,
regional lymphatics, and blood.
References
• IRX-2 was well tolerated, with no treatment-related grade 3 or 4 toxicities or surgical delays;
• In breast cancer, IRX-2 enhances TIL recruitment and PD-L1 expression (by mRNA and mIHC);
• Peripheral immune changes were associated with Cy administration but not IRX-2 injections;
• These preliminary findings will be further explored in a follow-up clinical trial that compares anti-PD-
1 +/- IRX-2 as induction therapy preceding neoadjuvant chemotherapy in stage II-III triple negative
breast cancer, with a primary endpoint of pathologic complete response rate
Portland, OR
Figure 2: sTIL increases After IRX-2 Therapy 
Fig.2 (a) Representative H&E demonstrating an increase in TILs in an ESBC patient. (b) In ESBC, treatment was
associated with a mean relative increase in TILs of 116% by Salgado scoring (range –36% to +1275%, p* = 0.02).
(c) In HNSCC, treatment was associated with a mean relative increase in TILs of 58% (range -57 to +452%,
p*=0.01). (a-c) TILs were scored by two independent pathologists for ESBC and HNSCC trial. ESBC; n=16;
HNSCC; n=36.
No treatment-related grade 3/4 toxicities
Figure 4: IRX-2 Increases immune checkpoint, leukocyte recruitment, 
cytotoxic T-cell, and leukocyte genes expression
Figure 5: Effects on peripheral T-cells 
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Exploratory Endpoints: RNA Analysis Exploratory Endpoints: Immune Monitoring
Fig.3 (a) Representative H&E, PerkinElmer multispectral immunohistochemistry (mIHC), and PD-L1
immunofluorescence before and after treatment; (b) mean PD-L1 per-cell fluorescence before versus after
treatment, shown by breast cancer subtype. Increases were observed in 12/15 patients (p=.07, Wilcoxon
matched-pairs rank test); (c) mRNA transcript levels of PD-L1 by Nanostring increased after IRX-2 treatment in
11/15 breast cancer patients (p=.04, Wilcoxon matched-pairs rank test).
Secondary EndpointsBackground
Toxicity
Grade I/II,  
any 
attribution (%)
Grade I/II, 
attributed to 
Cy (%)
Grade I/II, 
attributed 
to Indo (%)
Grade I/II, 
attributed to 
IRX-2 (%)
Nausea 13 (81%) 3 (19%) 8 (50%)
Bruising 8 (50%) 7 (44%)
Fatigue 9 (56%) 5 (31%)
Injection site reaction 8 (50%) 8 (50%)
Abdominal 
cramping/bloating 4 (25%) 3 (19%)
Increased ALT/AST/AlkP 4 (25%)
Anemia 4 (25%) 1 (6%) 1 (6%)
Headache 5 (31%) 1 (6%)
Hypokalemia 4 (25%)
Anorexia 3 (19%)
Diarrhea 3 (19%) 1 (6%) 1 (6%)
Flatulence 3 (19%) 2 (13%)
Injection site pain 3 (19%) 3 (19%)
Vomiting 3 (19%) 2 (13%) 2 (13%)
Figure 3: PD-L1 increases After IRX-2 Therapy (IHC and Nanostring)
Fig.4 (a-d) mRNA expression
from breast tissue, before
versus after treatment, were
analyzed using Nanostring
pan-cancer immune panel.
Heat maps represent log2-
transformed fold-change in
RNA expression levels.
Purple indicates increases in
relative expression, whereas
beige indicates decreases.
Four RNA signatures were
established evaluating
markers for leukocyte
recruitment, cytotoxic T
cells, leukocyte markers, and
checkpoints. Trends toward
increased T- cells
recruitment markers were
observed with the illustrated
panels
(e) % fold change in
Nanostring cell type
frequencies, representing an
average of functional genes
associated with each
immune cell type.
(f) Volcano plot showing fold
change in individual genes
(blue: p<.05; red p<.01)
HNSCCESBC
Fig.5-III. Cy is associated with sustained
decreases in B-cell populations,
including total B-cells, transitioning B-
cells, naïve B-cells, and pre-switched B-
cells, but not plasma cells, n=16.
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Fig.5-I Peripheral blood flow
cytometry. (a-c) Cy is associated
with transient decreases in
absolute numbers of CD3, CD4 and
CD8 T-cells, and (d-f) transient
decreases in T-regs, Treg
proliferation (Ki67), and function
(GzmB), n=16.
Fig.5-II. No changes in % of dendritic cells 
(DC’s), DC activation markers (CD40, CD86) 
or myeloid-derived suppressor cells (MDSCs) 
were observed, n=16.
Table 2. Treatment-related toxicities occurring in >15% of subjects. (Note:
transient treatment-unrelated grade III syncope was observed in one
subject with prior history of vasovagal syncope)
Table 1: Demographics and tumor characteristics of participants.
Legend: Cy=cyclophosphamide; Sx=surgery; MDSC=myeloid-derived suppressor cells 
